Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Cash from Operations (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Cash from Operations for 11 consecutive years, with 5244000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 9.59% to 5244000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 212000.0 through Dec 2025, up 99.11% year-over-year, with the annual reading at 25600000.0 for FY2025, 7.56% down from the prior year.
  • Cash from Operations hit 5244000.0 in Q4 2025 for Aptevo Therapeutics, down from 18700000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 18700000.0 in Q3 2025 to a low of 7504000.0 in Q1 2021.
  • Historically, Cash from Operations has averaged 3920650.0 across 5 years, with a median of 5243000.0 in 2021.
  • Biggest five-year swings in Cash from Operations: tumbled 245.66% in 2024 and later skyrocketed 459.89% in 2025.
  • Year by year, Cash from Operations stood at 3880000.0 in 2021, then tumbled by 53.07% to 5939000.0 in 2022, then increased by 12.06% to 5223000.0 in 2023, then fell by 11.05% to 5800000.0 in 2024, then grew by 9.59% to 5244000.0 in 2025.
  • Business Quant data shows Cash from Operations for APVO at 5244000.0 in Q4 2025, 18700000.0 in Q3 2025, and 7068000.0 in Q2 2025.